Plaque Psoriasis Flashcards
Guidelines for psoriasis
2019 Joint American Academy of Dermatology Association and National Psoriasis Foundation (AAD-NPF)
Current recommended classes for psoriasis
- TNFa inhibitors
- IL12/IL23 Inhibitors
- IL17 inhibitors
- IL23 inhibitors
TNFa inhbitors (4) recommended for psoriasis
- Enbrel (etanercept)
- Remicade (infliximab)
- Humira (adalimumab)
- Cimzia (certolizumab)
IL12/23 inhibitor (1) recommended for psoriasis
- Stelara (ustekinumab)
IL 17 inhibitors recommended for psoriasis (3)
- Cosentyx (secukinumab)
- Taltz (ixekizumab)
- Siliq (brodalumab)
IL 23 inhibitors recommended for psoriasis (3)
- Tremfya (guselkumab)
- Ilumya, Ilumetri (tildrakizumab)
- Skyrizi (risankizumab)
Generic and class: Skyrizi
Skyrizi (risankizumab), IL23
Generic and class: Enbrel
Etanercept, TNFai
Generic and class: Cosentyx
Secukinumab, IL17i
Generic and class: Tremfya
Guselkumab, IL23
Generic and class: Remicade
infliximab, TNFa
Generic and class: Humira
adalimumab, TNFa
Generic and class: Ilumya, Ilumetri
tildrakizumab
Generic and class: Taltz
Ixekizumab, IL17
Generic and class: Siliq
Brodalumab, IL17
Generic and class: Stelara
Ustekinumab, IL12/23
Recommendation for TNFa inhibitors and IL-12/23
may be used in combination with Otezla (apremilast)
Combination therapy for psoriasis options
- TNFa + Otezla (apremilast)
- IL12/23 + Otezla (apremilast)
- Acetretin
- cyclosporine
- methotrexate
- UV phototherapy
First and only topical PDE4i for plaque psoriasis
Zoryve (roflumilast)
Pricing for Zoryve 60 g tube
$800-$1k
When was Zoryve approved for topical treatment of plaque psoriasis including intertriginous areas
2023
age for patients to take Zoryve
12 andolder
Oral PDE4i approved in 2014 for the treatment of psoriatic arthritis and plaque psoriasis in patients wo are candidates for phototherapy or systemic therapy
Otezla (apremilast)
Otezla (apremilast) pricing
$5k-$8k for 60, 30 mg tablets
Topical PDE4i approved in 2016 for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months and older
Eucrisa (crisabarole)
Eucrisa (crisabarole) pricing
$800-$900 for 60 g tube
Roflumilast was approved in 2011 for what indication and under what brand name?
Daliresp, for COPD
Roflumilast is water/lipid INsoluble?
water-insoluble
Which PDE enzymes does roflumilast affect?
just PDE4
Where is PDE4 expressed? (4)
- Keratinocytes
- Neutrophils
- Langerhans cells
- T cells
In which cells do the expressoin of PDE4 lead to plaque formation?
T cells
By breaking down cAMP, PDE4 modulates (5)
- pro/anti-inflammatory cytokine synthesis
- T cell activation
- neutrophil degranulation
- Ag-presentation
- immune cell proliferation
Roflumilast MoA
inhibits the PDE4 isoenzyme and prevents cAMP hydrolysis, increasing INTRACELLULAR cAMP
Increased intracellular cAMP leads to: (4)
- inhibition of O2 formulation in epithelial cells, neutrophils, and smooth muscle cells
- inhibition of smooth muscle and inflammatory cell proliferation
- inhibition of fibroblasts
- inhibition of mucus production
Increasing intracellular cAMP in patients with COPD specifically results in
- decreased cytokine release
- decreased inflammatory mediators
- decreased expression of cell surface markers
- decreased apoptosis
What role does roflumilast have in COPD?
increases lung function, decreases frequency of exacerbations in patients with severe COPD associated with chronic bronchitis
PSORRO trial
Efficacy and Safety of Oral Roflumilast for Moderate-to-Severe Psoriasis; multi-center, company-independent, randomized, double-blind, placebo controlled trial
PSORRO trial methods
1:1 randomized, PO roflumilast 500 μg or placebo, and at week 12 patients were switched to open-label roflumilast through week 24
primary endpoint for PSORRO
≥75% greater reduction in baseline PASI75 at week 12
PASI75
a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement.
PSORRO trial week 12 results
35% (8 patients) achieved PASI75 vs 0 in placebo
PSORRO trial week 24 results
PASI50: 65%
PASI75: 44%
PASI90: 22%
PASI100: 9%
PSORRO n=
46
Zoryve cream/foam is formulated with HYDROARQ technology?
cream
HYDROARQ Technology
suspends API in pH-balanced suspension, free from excipients, irritants, fragrances, and gluten
Zoryve cream is the first drug formulated with ____, a novel emulsifier with non-ceramide stripping properties
Crodafos CES